Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT

Luca Arcaini, S. Burcheri, A. Rossi, M. Paulli, R. Bruno, F. Passamonti, E. Brusamolino, A. Molteni, A. Pulsoni, M. C. Cox, L. Orsucci, A. Fabbri, M. Frezzato, M. T. Voso, F. Zaja, F. Montanari, M. Merli, C. Pascutto, E. Morra, S. CortelazzoM. Lazzarino

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Background: Hepatitis C virus (HCV) infection is frequently associated with B-cell non-Hodgkin's lymphomas. We investigated the prevalence of HCV infection in nongastric marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT) in order to define the relationship between the viral infection and the presenting features, treatment, and outcome. Methods: We retrospectively studied 172 patients with a histological diagnosis of marginal zone B-cell lymphoma of MALT, except for stomach, and with available HCV serology, among a series of 208 patients. Results: HCV infection was documented in 60 patients (35%). Most HCV-positive patients (97%) showed a single MALT organ involvement. HCV-positive patients showed a more frequent involvement of skin (35%), salivary glands (25%), and orbit (15%). The majority of stage IV HCV-positive patients (71%) had a single MALT site with bone marrow involvement. The overall response rate was similar in HCV-positive (93%) and HCV-negative patients (87%). Overall survival (OS) and event-free survival (EFS) did not differ according to HCV infection. In multivariate analysis, advanced disease (stage III-IV) was associated with a poorer OS (P = 0.0001), irrespective of HCV serostatus. Conclusions: This study shows that nongastric marginal zone lymphomas are characterized by a high prevalence of HCV infection. Patients with involvement of a single MALT site have the highest prevalence of HCV. HCV-positive nongastric lymphomas of MALT show an indolent course similar to HCV-negative patients and seem an ideal target for exploiting the antilymphoma activity of antiviral treatments.

Original languageEnglish
Pages (from-to)346-350
Number of pages5
JournalAnnals of Oncology
Volume18
Issue number2
DOIs
Publication statusPublished - Feb 2007

Fingerprint

Marginal Zone B-Cell Lymphoma
Virus Diseases
Hepacivirus
Lymphoid Tissue
Mucous Membrane
Survival
B-Cell Lymphoma
Orbit
Serology
Salivary Glands

Keywords

  • Hepatitis C virus
  • Infectious agents
  • MALT lymphoma
  • Marginal zone

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. / Arcaini, Luca; Burcheri, S.; Rossi, A.; Paulli, M.; Bruno, R.; Passamonti, F.; Brusamolino, E.; Molteni, A.; Pulsoni, A.; Cox, M. C.; Orsucci, L.; Fabbri, A.; Frezzato, M.; Voso, M. T.; Zaja, F.; Montanari, F.; Merli, M.; Pascutto, C.; Morra, E.; Cortelazzo, S.; Lazzarino, M.

In: Annals of Oncology, Vol. 18, No. 2, 02.2007, p. 346-350.

Research output: Contribution to journalArticle

Arcaini, L, Burcheri, S, Rossi, A, Paulli, M, Bruno, R, Passamonti, F, Brusamolino, E, Molteni, A, Pulsoni, A, Cox, MC, Orsucci, L, Fabbri, A, Frezzato, M, Voso, MT, Zaja, F, Montanari, F, Merli, M, Pascutto, C, Morra, E, Cortelazzo, S & Lazzarino, M 2007, 'Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT', Annals of Oncology, vol. 18, no. 2, pp. 346-350. https://doi.org/10.1093/annonc/mdl388
Arcaini, Luca ; Burcheri, S. ; Rossi, A. ; Paulli, M. ; Bruno, R. ; Passamonti, F. ; Brusamolino, E. ; Molteni, A. ; Pulsoni, A. ; Cox, M. C. ; Orsucci, L. ; Fabbri, A. ; Frezzato, M. ; Voso, M. T. ; Zaja, F. ; Montanari, F. ; Merli, M. ; Pascutto, C. ; Morra, E. ; Cortelazzo, S. ; Lazzarino, M. / Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. In: Annals of Oncology. 2007 ; Vol. 18, No. 2. pp. 346-350.
@article{66ee64f49f9749bdac7bac5009853a30,
title = "Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT",
abstract = "Background: Hepatitis C virus (HCV) infection is frequently associated with B-cell non-Hodgkin's lymphomas. We investigated the prevalence of HCV infection in nongastric marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT) in order to define the relationship between the viral infection and the presenting features, treatment, and outcome. Methods: We retrospectively studied 172 patients with a histological diagnosis of marginal zone B-cell lymphoma of MALT, except for stomach, and with available HCV serology, among a series of 208 patients. Results: HCV infection was documented in 60 patients (35{\%}). Most HCV-positive patients (97{\%}) showed a single MALT organ involvement. HCV-positive patients showed a more frequent involvement of skin (35{\%}), salivary glands (25{\%}), and orbit (15{\%}). The majority of stage IV HCV-positive patients (71{\%}) had a single MALT site with bone marrow involvement. The overall response rate was similar in HCV-positive (93{\%}) and HCV-negative patients (87{\%}). Overall survival (OS) and event-free survival (EFS) did not differ according to HCV infection. In multivariate analysis, advanced disease (stage III-IV) was associated with a poorer OS (P = 0.0001), irrespective of HCV serostatus. Conclusions: This study shows that nongastric marginal zone lymphomas are characterized by a high prevalence of HCV infection. Patients with involvement of a single MALT site have the highest prevalence of HCV. HCV-positive nongastric lymphomas of MALT show an indolent course similar to HCV-negative patients and seem an ideal target for exploiting the antilymphoma activity of antiviral treatments.",
keywords = "Hepatitis C virus, Infectious agents, MALT lymphoma, Marginal zone",
author = "Luca Arcaini and S. Burcheri and A. Rossi and M. Paulli and R. Bruno and F. Passamonti and E. Brusamolino and A. Molteni and A. Pulsoni and Cox, {M. C.} and L. Orsucci and A. Fabbri and M. Frezzato and Voso, {M. T.} and F. Zaja and F. Montanari and M. Merli and C. Pascutto and E. Morra and S. Cortelazzo and M. Lazzarino",
year = "2007",
month = "2",
doi = "10.1093/annonc/mdl388",
language = "English",
volume = "18",
pages = "346--350",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "2",

}

TY - JOUR

T1 - Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT

AU - Arcaini, Luca

AU - Burcheri, S.

AU - Rossi, A.

AU - Paulli, M.

AU - Bruno, R.

AU - Passamonti, F.

AU - Brusamolino, E.

AU - Molteni, A.

AU - Pulsoni, A.

AU - Cox, M. C.

AU - Orsucci, L.

AU - Fabbri, A.

AU - Frezzato, M.

AU - Voso, M. T.

AU - Zaja, F.

AU - Montanari, F.

AU - Merli, M.

AU - Pascutto, C.

AU - Morra, E.

AU - Cortelazzo, S.

AU - Lazzarino, M.

PY - 2007/2

Y1 - 2007/2

N2 - Background: Hepatitis C virus (HCV) infection is frequently associated with B-cell non-Hodgkin's lymphomas. We investigated the prevalence of HCV infection in nongastric marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT) in order to define the relationship between the viral infection and the presenting features, treatment, and outcome. Methods: We retrospectively studied 172 patients with a histological diagnosis of marginal zone B-cell lymphoma of MALT, except for stomach, and with available HCV serology, among a series of 208 patients. Results: HCV infection was documented in 60 patients (35%). Most HCV-positive patients (97%) showed a single MALT organ involvement. HCV-positive patients showed a more frequent involvement of skin (35%), salivary glands (25%), and orbit (15%). The majority of stage IV HCV-positive patients (71%) had a single MALT site with bone marrow involvement. The overall response rate was similar in HCV-positive (93%) and HCV-negative patients (87%). Overall survival (OS) and event-free survival (EFS) did not differ according to HCV infection. In multivariate analysis, advanced disease (stage III-IV) was associated with a poorer OS (P = 0.0001), irrespective of HCV serostatus. Conclusions: This study shows that nongastric marginal zone lymphomas are characterized by a high prevalence of HCV infection. Patients with involvement of a single MALT site have the highest prevalence of HCV. HCV-positive nongastric lymphomas of MALT show an indolent course similar to HCV-negative patients and seem an ideal target for exploiting the antilymphoma activity of antiviral treatments.

AB - Background: Hepatitis C virus (HCV) infection is frequently associated with B-cell non-Hodgkin's lymphomas. We investigated the prevalence of HCV infection in nongastric marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT) in order to define the relationship between the viral infection and the presenting features, treatment, and outcome. Methods: We retrospectively studied 172 patients with a histological diagnosis of marginal zone B-cell lymphoma of MALT, except for stomach, and with available HCV serology, among a series of 208 patients. Results: HCV infection was documented in 60 patients (35%). Most HCV-positive patients (97%) showed a single MALT organ involvement. HCV-positive patients showed a more frequent involvement of skin (35%), salivary glands (25%), and orbit (15%). The majority of stage IV HCV-positive patients (71%) had a single MALT site with bone marrow involvement. The overall response rate was similar in HCV-positive (93%) and HCV-negative patients (87%). Overall survival (OS) and event-free survival (EFS) did not differ according to HCV infection. In multivariate analysis, advanced disease (stage III-IV) was associated with a poorer OS (P = 0.0001), irrespective of HCV serostatus. Conclusions: This study shows that nongastric marginal zone lymphomas are characterized by a high prevalence of HCV infection. Patients with involvement of a single MALT site have the highest prevalence of HCV. HCV-positive nongastric lymphomas of MALT show an indolent course similar to HCV-negative patients and seem an ideal target for exploiting the antilymphoma activity of antiviral treatments.

KW - Hepatitis C virus

KW - Infectious agents

KW - MALT lymphoma

KW - Marginal zone

UR - http://www.scopus.com/inward/record.url?scp=33847305351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847305351&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdl388

DO - 10.1093/annonc/mdl388

M3 - Article

C2 - 17071937

AN - SCOPUS:33847305351

VL - 18

SP - 346

EP - 350

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

ER -